meta
|
evidence
oncology
Living systematic review and meta-analysis
metastatic/adv melanoma (mML)
mML - (neo)adjuvant (NA)
mML - NA - all population
9
mML - NA - PDL1 positive
1
mML - 1st line (L1)
mML - L1 - all population
7
mML - L1 - BRAF mutant
2
mML - L1 - BRAF wild
3
mML - 2nd line (L2)
mML - L2 - all population
11
mML - L2 - BRAF mutant
1
mesothelioma (MS)
immune chekpoint inhibitors
anti-CTLA-4
ipilimumab based treatment
ipilimumab alone
Ipilimumab (10 mg/kg)
anti-PD-(L)1
nivolumab based treatment
nivolumab alone
pembrolizumab based treatment
pembrolizumab alone
Immune checkpoint association
nivolumab plus ipilimumab
versus all
vs immune chekpoint inhibitors
vs anti-CTLA-4
vs ipilimumab based treatment
vs ipilimumab alone
vs Ipilimumab (10 mg/kg)
vs anti-PD-(L)1
vs nivolumab based treatment
vs nivolumab alone
vs Immunostimulant
vs interferon alpha
vs non active control
vs placebo
All patients
Age < 65y (younger)
Age > 65y
BRAF mutant
BRAF wild type
Gender, female
Gender, male
PD-L1 < 5%
PD-L1 > 5%
stage IIIb
stage IIIc
stage IV (metastatic)
stage M1A
stage M1B
stage M1C
stage M1C (with brain metastasis)
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
button
bars
forest
bayes
pooled
summary
circles
deaths (OS)
MFS
RFS (extension)
RFS/DFS
AE (any grade)
AE (grade 3-4)
AE leading to death (grade 5)
AE leading to treatment discontinuation (any grade)
AE leading to treatment discontinuation (grade 3-4)
SAE (any grade)
SAE (grade 3-4)
STRAE (any grade)
STRAE (grade 3-4)
TRAE (any grade)
TRAE (grade 3-4)
TRAE leading to death (grade 5)
TRAE leading to discontinuation (any grade)
TRAE leading to discontinuation (grade 3-4)
Abdominal pain TRAE (grade 3-4)
Acute kidney injury TRAE (grade 3-4)
Adrenal insufficiency TRAE (grade 3-4)
Alopecia TRAE (grade 3-4)
Anaemia TRAE (grade 3-4)
Arthralgia TRAE (grade 3-4)
Asthenia TRAE (grade 3-4)
Blood and lymphatic system disorders TRAE (grade 3-4)
Blood creatinine increased TRAE (grade 3-4)
Chills TRAE (grade 3-4)
Colitis TRAE (grade 3-4)
Cough TRAE (grade 3-4)
Decreased appetite TRAE (grade 3-4)
Diabetes TRAE (grade 3-4)
Diarrhoea TRAE (grade 3-4)
Dizziness TRAE (grade 3-4)
Dry skin TRAE (grade 3-4)
Dysgeusia TRAE (grade 3-4)
Dyspepsia TRAE (grade 3-4)
Dyspnoea TRAE (grade 3-4)
Endocrine disorders TRAE (grade 3-4)
Eye disorders TRAE (grade 3-4)
Fatigue TRAE (grade 3-4)
Gastritis TRAE (grade 3-4)
Gastrointestinal disorders TRAE (grade 3-4)
General disorders and administration site conditions TRAE (grade 3-4)
Headache TRAE (grade 3-4)
Hepatitis TRAE (grade 3-4)
Hepatobiliary disorders TRAE (grade 3-4)
Hypersensitivity TRAE (grade 3-4)
Hypertension TRAE (grade 3-4)
Hyperthyroidism TRAE (grade 3-4)
Hypophysitis TRAE (grade 3-4)
Hypothyroidism TRAE (grade 3-4)
Increase AST TRAE (grade 3-4)
Increased ALT TRAE (grade 3-4)
Increased lipase level TRAE (grade 3-4)
Infusion-related reactions TRAE (grade 3-4)
Leucopenia TRAE (grade 3-4)
Maculopapular rash TRAE (grade 3-4)
Metabolism and nutrition disorders TRAE (grade 3-4)
Musculoskeletal and connective tissue disorders TRAE (grade 3-4)
Myalgia TRAE (grade 3-4)
Myositis TRAE (grade 3-4)
Nausea TRAE (grade 3-4)
Nervous system disorders TRAE (grade 3-4)
Neutropenia TRAE (grade 3-4)
Palmar-plantar erythrodysaesthesia syndrome TRAE (grade 3-4)
Pancreatitis TRAE (grade 3-4)
Paraesthesia TRAE (grade 3-4)
Peripheral neuropathy TRAE (grade 3-4)
Pneumonitis TRAE (grade 3-4)
Pruritus TRAE (grade 3-4)
Pyrexia TRAE (grade 3-4)
Rash TRAE (grade 3-4)
Renal and urinary disorders TRAE (grade 3-4)
Respiratory, thoracic and mediastinal disorders TRAE (grade 3-4)
Sarcoidosis TRAE (grade 3-4)
Skin and subcutaneous tissue disorders TRAE (grade 3-4)
Stomatitis TRAE (grade 3-4)
Thrombocytopenia TRAE (grade 3-4)
Thyroiditis TRAE (grade 3-4)
Uveitis TRAE (grade 3-4)
Vitiligo TRAE (grade 3-4)
Vomiting TRAE (grade 3-4)
Weight decreased TRAE (grade 3-4)
deaths (OS)
mML - NA - all population
metastatic/adv melanoma (mML)
mML - (neo)adjuvant (NA)
mML - NA - all population
versus Ipilimumab (10 mg/kg)
nivolumab alone vs. Ipilimumab (10 mg/kg)
1
certainty unassessable
-12%
versus placebo
nivolumab alone vs. placebo
1
-
×
delta: difference in rate or median (if available)
×
Extraction panel open
An extraction panel is open